Download Support Materials
For US residents only.
From diagnosis to treatment with TABRECTA® (capmatinib) tablets
Sharon, an actual patient taking TABRECTA, was diagnosed with metastatic non-small cell lung cancer (mNSCLC). At first, she and her husband Donnie were overwhelmed by her diagnosis, but with the guidance of her oncologist and the results of her comprehensive biomarker test, she was able to get a treatment that’s a match for her specific type of cancer. View the videos below to hear Sharon and Donnie's story.
MEET SHARON: Treatment Experience
Sharon describes her experience on TABRECTA as her first-line treatment, including side effects.
MEET SHARON: Taking TABRECTASharon discusses how she incorporates taking TABRECTA into her daily routine.
MEET SHARON: Uncovering METex14 Through Comprehensive Biomarker Testing
With the help of her oncologist, Sharon discovers via comprehensive biomarker testing that she has the MET exon 14 skipping (METex14) biomarker. Thanks to this specific test, her doctor is able to recommend TABRECTA as her first course of treatment.
MEET SHARON: Finding Strength Through Support
Knowing how important the right support system is, Sharon shares how she has found comfort and courage both online and through her fiercest advocate and companion, her husband Donnie.